These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. A Case Report of Kidney Transplantation in a Patient With Pre-existing Chronic Myeloid Leukemia: The Role of Achieving Molecular Response and Treatment-Free Remission. Pinlac V; Bonifacio L Transplant Proc; 2024 Apr; 56(3):738-741. PubMed ID: 38538381 [TBL] [Abstract][Full Text] [Related]
23. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237 [TBL] [Abstract][Full Text] [Related]
24. [Comparison of nilotinib Yu L; Qin YZ; Lai YY; Shi HX; Huang XJ; Hou Y; Jiang Q Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):996-1002. PubMed ID: 32023729 [No Abstract] [Full Text] [Related]
25. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226 [TBL] [Abstract][Full Text] [Related]
30. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group. Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131 [TBL] [Abstract][Full Text] [Related]
31. Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes. Stuckey R; Casado LF; Colomer D; Gómez-Casares MT; Casas L; García-Gutierrez V; Sastre JL; Ramírez-Payer Á; Vall-Llovera F; Goñi MÁ; Xicoy B; Godoy AC; Núñez J; Mora I; Vallansot R; López-Lorenzo JL; Palomera L; Conesa V; Noya MS; Sánchez-Guijo F; Peña A; Bautista G; Steegmann JL J Mol Diagn; 2020 Oct; 22(10):1217-1224. PubMed ID: 32688056 [TBL] [Abstract][Full Text] [Related]
32. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial. Nakamae H; Fukuda T; Nakaseko C; Kanda Y; Ohmine K; Ono T; Matsumura I; Matsuda A; Aoki M; Ito K; Shibayama H Int J Hematol; 2018 Mar; 107(3):327-336. PubMed ID: 29076005 [TBL] [Abstract][Full Text] [Related]
33. Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry). Möbius S; Schenk T; Himsel D; Maier J; Franke GN; Saussele S; Pott C; Andrikovics H; Meggyesi N; Machova-Polakova K; Zizkova H; Jurcek T; Mesanovic S; Zadro R; Gottardi E; Haenig J; Schuld P; Cross NCP; Hochhaus A; Ernst T J Cancer Res Clin Oncol; 2019 Jun; 145(6):1645-1650. PubMed ID: 30941573 [TBL] [Abstract][Full Text] [Related]
34. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106 [TBL] [Abstract][Full Text] [Related]
35. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial). Ishikawa J; Matsumura I; Kawaguchi T; Kuroda J; Nakamae H; Miyamoto T; Matsuoka KI; Shibayama H; Hino M; Hirase C; Kamimura T; Shimose T; Akashi K; Kanakura Y Int J Hematol; 2018 May; 107(5):535-540. PubMed ID: 29362980 [TBL] [Abstract][Full Text] [Related]
37. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758 [TBL] [Abstract][Full Text] [Related]
38. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience. Ribeiro BF; Miranda EC; Albuquerque DM; Delamain MT; Oliveira-Duarte G; Almeida MH; Vergílio B; Silveira RA; Oliveira-Duarte V; Lorand-Metze I; De Souza CA; Pagnano KB Clinics (Sao Paulo); 2015 Aug; 70(8):550-5. PubMed ID: 26247667 [TBL] [Abstract][Full Text] [Related]
39. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib. Erba HP; Pham DC; Zaiden R; Vu H; Tai S Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576 [TBL] [Abstract][Full Text] [Related]
40. Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia. Wang R; Cong Y; Li C; Zhang C; Lin H Medicine (Baltimore); 2019 Apr; 98(15):e15222. PubMed ID: 30985724 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]